Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019

Apexigen Presents Clinical Data On CD40 Antibody APX005M In Metastatic Melanoma At The AACR Annual Meeting 2019

Publication date: Apr 02, 2019

SAN CARLOS, Calif. , April 1, 2019 /PRNewswire/ — Apexigen, Inc. , a clinical-stage biopharmaceutical company, today presented new clinical data on APX005M at the American Association for Cancer Research (AACR) Annual Meeting, taking place March 29 – April 3, 2019 in Atlanta, GA.

“We are excited to have new clinical data presented at AACR on our CD40 antibody APX005M in combination therapy, highlighting the breadth of our clinical development program targeting difficult-to-treat types of cancer,” said Ovid Trifan, M. D., Ph. D., Chief Medical Officer and Senior Vice President of Clinical Development of Apexigen.

“Yesterday, clinical data in metastatic pancreatic cancer were presented in a plenary session, showing APX005M in combination therapy was well-tolerated and induced promising tumor shrinkage in 20 of 24 evaluable patients.

Today, we are presenting clinical data from our ongoing Phase 1b/2 clinical trial in patients with metastatic melanoma demonstrating that APX005M is well tolerated in combination with nivolumab and triggers responses in patients who have progressed on anti-PD-1 therapy.

The Phase 2 dose-expansion portion of this clinical trial followed a Simon 2-stage design and included two parallel cohorts of patients treated with the RP2D of APX005M with nivolumab.

For additional information on this trial (NCT03123783), please visit Data Presentation at AACR 2019 Annual Meeting Late-breaking Abstract Title: Phase Ib/II clinical trial of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC) (Abstract #CT089) Poster Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM ET Poster Session: Phase 1 Clinical Trials Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 16 About APX005M APX005M is a humanized monoclonal antibody designed to stimulate the anti-tumor immune response.

APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, melanoma, esophageal and gastroesophageal junction cancers, non-small cell lung cancer, renal cell carcinoma, sarcomas, and pediatric brain cancer in various combinations with immunotherapy, a cancer vaccine, chemotherapy or radiation therapy.

Concepts Keywords
AACR Medical specialties
ADA Monoclonal antibodies
Agonistic Antineoplastic drugs
Antibodies Bristol-Myers Squibb
Antibody Immune system
Antigen Chemotherapy
Atlanta Radiation
B Cells Antibodies
Biopharmaceutical Monoclonal antibody therapy
BRAF Checkpoint inhibitor
Brain Nivolumab
Bristol Myers Squibb Cancer treatments
Cancer Clinical medicine
CD40 Medicine
Chemotherapy Immunotherapy
Clinical Trial Chemotherapy
Clinical Trials Radiation therapy
Cohort Patient metastatic melanoma
Combination Therapy NSCLC
Congress Stage biopharmaceutical
Dendritic Cells Tumor
DOR
Gastroesophageal Junction
Georgia
Humanized Monoclonal Antibody
Immune Response
Immune System
Immunotherapy
Incidence
Lung
Lung Cancer
Macrophages
Maximum Tolerated Dose
Melanoma
Metastatic
Monoclonal Antibody
Monocytes
Mutation
Oncology
Ovid
Pancreatic Cancer
Pediatric
Pharmacokinetic
Plenary Session
Primary Endpoint
Progressive
Radiation Therapy
Receptor
Renal Carcinoma
SAN CARLOS
Sarcomas
Time
Tumor
Vaccine
Vice President
Yale

Semantics

Type Source Name
gene UNIPROT OPRD1
drug DRUGBANK Coenzyme M
disease DOID brain cancer
disease MESH sarcomas
pathway BSID Renal cell carcinoma
disease DOID renal cell carcinoma
disease MESH renal cell carcinoma
pathway BSID Immune System
disease MESH multi
pathway BSID Non-small cell lung cancer
gene UNIPROT TP53INP2
disease MESH non-small cell lung cancer
disease DOID non-small cell lung cancer
gene UNIPROT DLST
gene UNIPROT BEST1
disease DOID ADA
gene UNIPROT MT1E
gene UNIPROT BRAF
gene UNIPROT PDCD1
disease DOID Cancer
gene UNIPROT CEP55
disease MESH multiple
disease MESH development
disease MESH pancreatic cancer
disease DOID pancreatic cancer
pathway BSID Pancreatic cancer
drug DRUGBANK Nivolumab
gene UNIPROT RPL17
disease MESH Cancer
drug DRUGBANK Nonoxynol-9
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT CNOT8
pathway BSID Melanoma
gene UNIPROT NAA50
disease DOID Melanoma
disease MESH Melanoma
gene UNIPROT CD40

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *